Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.

Drug Des Devel Ther · 2020 · PMC7153999 · PMID 32308371

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

While the 75 mg-dose group demonstrated an overall trend of composite clinical improvement compared to the placebo group, the differences only reached statistical significance in the IBS-3002 trial.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.